Shares of Biopharma Up After News of Uplisting

Shares of Biopharma Up After News of Uplisting

By: Tomas Ronolski - AllPennyStocks.com News

Thursday, April 25, 2024

When firms uplist to a higher exchange, they gain visibility and greater access to investors. And today, news of a strategic expansion in the United States is sending shares of this biopharma company up this morning despite a generally down-trending mood on the Street. NurExone Biologic Inc. (TSXV: NRX) (OTC: NRXBF), a pioneering biopharmaceutical company, announced in a press release today that its common shares are now quoted for trading on the OTCQB ® Venture Market under the symbol NRXBF. NurExone is developing a platform for biologically-guided exosome-based therapies to be delivered non-invasively to patients who have suffered central nervous system injuries. NurExone is the sole public company developing therapies for spinal cord injury treatment with exosomes. 

Trading access on the OTCQB is a pivotal gateway to U.S. trading. The firm also announced it received Depository Trust Company eligibility, which expands the stock’s reach to an even wider audience of potential investors.

According to NurExone CEO Dr. Lior Shaltiel, “Expanding our investor base will accelerate our efforts in developing solutions and therapies for the hundreds of thousands of patients worldwide suffering from traumatic spinal cord injuries.”

Canadian shares were trading up at $0.64 in morning trade.

 


Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares on the Rise Following Partnership News With Major Potato Chip Brand
Slowing Growth Increases Hopes of a Rate Cut Pivot in Canada 
Re-Classification of Marijuana Sends Shares of Cannabis Operator on a Tear
Most Popular
FREE Newsletter


Back to Top